AZN · NYSE · STOCK
AstraZeneca (AZN) Stock Analysis
$159.18
52W $153.41 – $212.71
53/100
$246.90B
23.7
0.21
Is AZN Bullish or Bearish?
Mixed.
Innellis AI committee rates AstraZeneca PLC (AZN) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.08 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
Bear Case
- Price-to-book of 5.8x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Current ratio of 0.94 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 79%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.7% shows genuine earnings power backing the valuation
− Price-to-book of 5.8x prices in significant intangible value
Growth Analyst
neutral
53
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ EPS growing 25.9% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.94 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 53.1 to 53.1.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
42.9
Neutral
MACD Histogram
-0.444
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$153.46
Resistance
$196.41
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$159.83
Below
EMA 21
$161.36
Below
EMA 50
$164.08
Below
EMA 200
$158.20
Above
Fundamental Analysis
Valuation
71
Growth
48
Profitability
94
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
23.7×
P/B Ratio
4.87×
PEG Ratio
1.01
Dividend Yield
1.99%
52W High
$212.71
52W Low
$153.41
Quality & Growth
ROE
2107.2%
ROA
899.0%
Gross Margin
7926.9%
Operating Margin
2268.6%
Revenue Growth YoY
—
Debt / Equity
0.64
AI Fundamental Assessment
P/E ratio of 23.7 (inexpensive relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 21.1%; Return on assets of 9.0%; Net margin of 17.0%; Gross margin of 79.3%; Current ratio of 0.89 (tight short-term liquidity); Debt-to-equity of 0.64; Free cash flow per share is positive (5.44); Most recent quarter beat estimates by 3.1%; EPS growth decelerating (+21.7% -> +1.9% QoQ); Analyst estimates rising over recent quarters
Get the Full AZN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →